Objective: Rituximab has emerged as an efficacious option for drug-resistant myasthenia gravis (MG). However, reports published only describe the short-term follow-up of patients treated and little is known about their long-term clinical and immunologic evolution. Our objective was to report the clinical and immunologic long-term follow-up of 17 patients (6 MuSKϩMG and 11 AChRϩMG) and compare the response between AChRϩMG and MuSKϩMG patients.
The use of immunosuppressors for the treatment of myasthenia gravis (MG) has notably reduced mortality and improved quality of life. 1 However, a subgroup of patients with MG does not respond to this treatment despite the use of multiple combinations of drugs, and are known as drug-resistant patients. Patients with MG with antibodies to MuSK (MuSKϩMG) more frequently have a poorer response to standard therapies than patients with antibodies to AChR (AChRϩMG). 2 Recently, several authors have found that rituximab, a monoclonal antibody that targets the CD20 antigen in B cells, 3 is efficacious in the treatment of drugresistant MG. 4 However, these reports only describe the short-term follow-up, and little is known about their long-term clinical and immunologic evolution. Furthermore, the response in AChRϩMG and MuSKϩMG patients has not been compared.
We describe the clinical and immunologic follow-up of 17 patients with MG treated with rituximab. We found a long-term clinical benefit in most of them. This benefit was particularly robust for the MuSKϩMG patients.
METHODS Our primary research question was to establish if treatment with rituximab was effective and the response obtained was long-lasting in drug-resistant MG. This study provides Class IV evidence that rituximab improves the clinical and immunologic status of patients with MuSKϩMG.
Six MuSKϩMG and 11 AChRϩMG patients were treated with rituximab. All of them were resistant to previous therapies and were Class III to V in the Myasthenia Gravis Foundation America (MGFA) classification. 5 Our standard treatment protocol includes prednisone as first-line drug and second-line immunosuppressors (azathioprine followed by cyclosporine and finally mycophenolate, tacrolimus, or methotrexate) if the response is not adequate or the dose of prednisone required is higher than 40 mg every other day (revised in 6 ). Patients were considered drug-resistant when no significant clinical improvement was achieved after the patient had received prednisone and at least 3 second-line immunosuppressants. 6 Rituximab was administered at the standard dose of 375 mg/m 2 every week for 4 consecutive weeks and then monthly for the next 2 months. Repeat rituximab infusions were administered only when myasthenic symptoms reappeared and interfered with daily life activities. We determined the MGFA postintervention status every 3 months and recorded changes in treatment. 5 A patient was considered to have improvement if their status changed from MGFA-IV or V to MGFA IIIA or II, or from MGFA-III to MGFA-II.
Blood samples were obtained before the infusion and every 3 months during the first year of follow-up after treatment with rituximab. From that point on, blood samples were obtained at least twice a year. AChR and MuSK antibody titers of all the samples stored were determined in a single assay to avoid technical variability as previously reported. 7 Titer variation within the same patient was expressed as the percentage of decrease or increase compared to pretreatment levels. Lymphocyte subpopulations (B and T cells) and total immunoglobulin levels were analyzed before and after rituximab. To assess the effect of rituximab on long-lived plasma cells, we performed an ELISA for anti-tetanus toxoid immunoglobulin G (IgG) (ATT) according to the manufacturer's instructions (Binding Site, Birmingham, UK). IgG1 and IgG4 MuSK antibodies were studied using ELISA as previously described in 5 of the 6 MuSK patients. 8 2 and analysis of variance (ANOVA) tests were used to analyze differences between MuSKϩMG and AChRϩMG patients. A Kaplan-Meier survival curve was generated to study the duration of response to rituximab.
Standard protocol approvals, registration, and patient consents. The study was approved by the Ethics Committee at our institution and all patients gave informed written consent to participate in the study. Permission for compassionate use of rituximab was given by the Spanish Ministry of Health.
RESULTS
Seventeen drug-resistant patients with MG (mean age of all patients at infusion: 44.3 years, 15 women) were treated with rituximab between 2005 and 2010. Six of them were MuSKϩMG patients (5 IVB and 1 Class V) and represented 14.6% (6 out of 41) of our MuSKϩMG group. The remaining 11 patients were AChRϩMG (2 IIIA, 2 IIIB, 7 IVB, 1 V) and represented 2.7% (11 out of 399) of our generalized AChRϩMG patients. The percentage of drug-resistant patients differed between MuSKϩMG and AChRϩMG patients (14.6% vs 2.7%, 2 p Ͻ 0.004).
The mean disease duration before rituximab was initiated was 128 months in the MuSKϩMG group and 120 months in AChRϩMG group. Treatment was well-tolerated and the only side effects were facial flushing and a generalized skin rush during the infusion in 2 patients that resolved with parenteral hydrocortisone in both cases. After this, these patients received pretreatment with IV hydrocortisone and diphenhydramine.
The mean follow-up time was 31 months (4 -60 months). Treatment with rituximab resulted in a significant improvement in 16 of the 17 patients. There was no difference in the response obtained based on the disease duration before rituximab was indicated. The response was qualitatively different since all MuSKϩMG patients achieved a minimal manifestation status (MMS) 3 months after the treatment. After a mean follow-up of 35 months for the MuSKϩMG patients, all of them remained in MMS or remission status and none required further infusions (table) . The dose of prednisone was decreased after treatment (average dose before rituximab: 49 mg/day; at last visit: 6.5 mg/day), allowing concomitant immunosuppressants to be withdrawn (table) . Ten of the AChRϩMG patients had improved at 3-month follow-up. We were able to decrease the average dose of prednisone from 30.5 mg/day before rituximab to 17.2 mg/day at last visit. There were no significant changes in second-line immunosuppressants. Six of the 10 required reinfusion after a mean period of 17 months (6 -34 months) after the first dose. They improved again but none reached MMS or remission status (Kaplan-Meier p ϭ 0.04) (table) .
Peripheral B cells were completely depleted in all 17 patients as early as 15 days after the first infusion, while T-cell subpopulations remained unchanged. Three months after treatment, we observed a mean decrease of 20% in immunoglobulin M (IgM) levels in all patients, while IgG levels did not significantly change. Accordingly, no significant differences were detected in ATT IgG reactivity after treatment.
In the MuSKϩMG group, antibody titers decreased during follow-up (figure 1). This decline was significant as early as 3 months after administration of the first dose (mean decrement of 42.72%, ANOVA p ϭ 0.043). At the last follow up visit, a mean reduction of 86.7% in MuSK-ab titers was achieved (p ϭ 0.002, ANOVA). We also studied changes in the reactivity of MuSKspecific IgG subclasses after treatment with rituximab. We observed a significant decrease in the reactivity of IgG4 in all patients and in the reactivity of IgG1 in all but one patient ( figure 2) .
In the AChRϩMG group, antibody levels were variable and did not decrease significantly at 3 months or at the end of follow-up. DISCUSSION We demonstrate that rituximab induces a long-lasting clinical benefit in severely affected, drug-resistant patients with MG. All but one patient with MG showed improvement, minimal manifestations, or remission status. Nevertheless, this clinical benefit was better and lasted longer in the MuSKϩMG group.
Regarding the immune response, MuSK antibodies decreased dramatically during the follow-up after a single rituximab cycle. However, AChR antibodies remained at the same titers during the same period of time.
Rituximab has a low rate of secondary events in patients with autoimmune diseases. The most common side effects are related to the infusion of the drug and they can be easily be prevented by pretreatment with hydrocortisone and diphenhydramine. Despite this favorable side effects profile, cases of progressive multifocal leukoencephalopathy (PML) have occasionally been reported in patients with autoimmune diseases such as rheumatoid arthritis, having an estimated frequency of 1/25,000 treated cases. To date, there are no reports of patients with MG treated with rituximab who have developed PML, but close follow-up is recommended.
Our study is not the first to suggest the efficacy of rituximab in patients with MG. In previous reports, 96% (25/26) of MuSKϩMG patients and 81% (30/ 37) of AChRϩMG patients had a good clinical response after a mean follow-up of 19 months. 4, 9 However, data concerning the clinical and immunologic features in the long term are lacking and the response between both groups has not been compared. Our data, based on a long follow-up period, indicate that the response was better and more persis- tent in the MuSKϩMG group because all patients maintained a remission or minimal manifestations status 3 years after treatment. In contrast, among AChRϩMG patients we observed that 54% had relapses that required reinfusions and concurrent immunosuppressive treatment could not be reduced.
Differences in response to treatment may be explained by divergences in the pathogenesis of AChRϩMG and MuSKϩMG. First, the main antibody subtypes in AChRϩMG are IgG1 and IgG3, while in MuSKϩMG the main subtype is IgG4. Next, T-helper cells have been implicated in both AChRϩMG and MuSKϩMG, but whereas a T-helper 1 response is related to IgG1 and IgG3 production, T-helper 2 cells are involved in the generation of IgG4 antibodies. Finally, changes in thymus histology and the presence of antistriated muscle autoantibodies are frequent in AChRϩMG but rare in MuSKϩMG.
Mechanisms involved in the generation of an IgG4-mediated immunologic response are not well understood. Other authors have described a similar quick and long-lasting response to a single dose of rituximab in other IgG4-associated diseases such as pemphigus vulgaris. 10 Provided that rituximab does not affect long-lived plasma cells and based on the rapid post-treatment decrease in MuSK-ab titers seen in our study, we hypothesize that these IgG4 antibodies could essentially be produced by short-lived plasma cells. In support of this hypothesis, our patients' IgM levels, produced by short-lived plasma cells, decreased after treatment, while ATT IgG levels, produced by long-term plasma cells, remained stable. 10 Moreover, a switch of the main anti-MuSK isotype IgG4 to IgG1 after treatment, previously suggested to influence clinical fluctuations, was also observed in 3 of our MuSKϩMG patients. 8 Considering that rituximab treatment can prevent clinical relapses and restrain the immune response in drug-resistant MuSKϩMG over a long period of time, a prospective, double-blind, randomized, controlled trial should be conducted to explore its use as a first option treatment in these patients, especially if good tolerance and a favorable riskbenefit profile are confirmed.
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